These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 20555312)
1. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Nasrallah HA; Gopal S; Gassmann-Mayer C; Quiroz JA; Lim P; Eerdekens M; Yuen E; Hough D Neuropsychopharmacology; 2010 Sep; 35(10):2072-82. PubMed ID: 20555312 [TBL] [Abstract][Full Text] [Related]
2. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. Bossie CA; Sliwa JK; Ma YW; Fu DJ; Alphs L BMC Psychiatry; 2011 May; 11():79. PubMed ID: 21569242 [TBL] [Abstract][Full Text] [Related]
3. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Hough D; Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M Schizophr Res; 2010 Feb; 116(2-3):107-17. PubMed ID: 19959339 [TBL] [Abstract][Full Text] [Related]
4. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Kramer M; Litman R; Hough D; Lane R; Lim P; Liu Y; Eerdekens M Int J Neuropsychopharmacol; 2010 Jun; 13(5):635-47. PubMed ID: 19941696 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Gopal S; Hough DW; Xu H; Lull JM; Gassmann-Mayer C; Remmerie BM; Eerdekens MH; Brown DW Int Clin Psychopharmacol; 2010 Sep; 25(5):247-56. PubMed ID: 20389255 [TBL] [Abstract][Full Text] [Related]
6. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens. Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197 [TBL] [Abstract][Full Text] [Related]
7. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Li H; Rui Q; Ning X; Xu H; Gu N Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. McEvoy JP; Byerly M; Hamer RM; Dominik R; Swartz MS; Rosenheck RA; Ray N; Lamberti JS; Buckley PF; Wilkins TM; Stroup TS JAMA; 2014 May; 311(19):1978-87. PubMed ID: 24846035 [TBL] [Abstract][Full Text] [Related]
12. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. Gopal S; Vijapurkar U; Lim P; Morozova M; Eerdekens M; Hough D J Psychopharmacol; 2011 May; 25(5):685-97. PubMed ID: 20615933 [TBL] [Abstract][Full Text] [Related]
13. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. Coppola D; Liu Y; Gopal S; Remmerie B; Samtani MN; Hough DW; Nuamah I; Sulaiman A; Pandina G BMC Psychiatry; 2012 Mar; 12():26. PubMed ID: 22455454 [TBL] [Abstract][Full Text] [Related]
14. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Sliwa JK; Bossie CA; Ma YW; Alphs L Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106 [TBL] [Abstract][Full Text] [Related]
15. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Pandina G; Lane R; Gopal S; Gassmann-Mayer C; Hough D; Remmerie B; Simpson G Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):218-26. PubMed ID: 21092748 [TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. Pandina GJ; Lindenmayer JP; Lull J; Lim P; Gopal S; Herben V; Kusumakar V; Yuen E; Palumbo J J Clin Psychopharmacol; 2010 Jun; 30(3):235-44. PubMed ID: 20473057 [TBL] [Abstract][Full Text] [Related]
17. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Carter NJ Drugs; 2012 May; 72(8):1137-60. PubMed ID: 22571444 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. Meltzer HY; Bobo WV; Nuamah IF; Lane R; Hough D; Kramer M; Eerdekens M J Clin Psychiatry; 2008 May; 69(5):817-29. PubMed ID: 18466043 [TBL] [Abstract][Full Text] [Related]
19. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison. Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study. Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]